Home
    • Plans Blog Contact
    Zoetis Inc logo

    Zoetis Inc

    ZTS
    Last price US$75.69
    Market cap US$31.9b
    12M price change -50.50%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer TARO PHARMACEUTICAL INDUSTRIES LTDTARO Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Zoetis Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Zoetis Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $2.3B (+3% YoY); EPS was $1.53 (reported).

    Revenue $2.3B +3% YoY
    EPS $1.53 reported
    Net income $601M reported

    What changed

    • Revenue +3% YoY to $2.3B; EPS reported to $1.53.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 07, 2026 SEC filing 8-K May 07, 2026 SEC filing 10-K Feb 12, 2026 SEC filing 8-K Feb 12, 2026 Earnings release Earnings release Feb 12, 2026 SEC filing 8-K Nov 04, 2025 Earnings release Earnings release Nov 04, 2025 SEC filing 10-Q Nov 04, 2025 SEC filing 8-K Aug 05, 2025 Earnings release Earnings release Aug 05, 2025 SEC filing 10-Q Aug 05, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 5.00/5
    Zoetis Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc
    In Drug Manufacturers Specialty & Generic industry , Amphastar P , Prestige Consumer Healthcare , TARO PHARMACEUTICAL INDUSTRIES LTD are companies with high ratings.

    Return on Equity

    Score 4.71/5
    Zoetis Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b
    Thermo Fishe... TMO US$196.1b

    Net Margin

    Score 4.93/5
    Zoetis Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b
    Thermo Fishe... TMO US$196.1b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Amphastar P , Prestige Consumer Healthcare , TARO PHARMACEUTICAL INDUSTRIES LTD are companies with high ratings.

    Leverage

    Score 1.40/5
    Zoetis Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc have achieved high scores.
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b
    Thermo Fishe... TMO US$196.1b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Zoetis Inc logo

    Zoetis Inc

    US$75.69

    US$75.99

    +0.4% vs price

    US$31.9b

    -1.01%

    -50.50%